Holen Sie sich die Stockscreener-App
17.58
2.66%
-0.48
Schlusskurs vom Vortag:
$18.06
Offen:
$18.09
24-Stunden-Volumen:
1.37M
Relative Volume:
0.53
Marktkapitalisierung:
$3.25B
Einnahmen:
$797.73M
Nettoeinkommen (Verlust:
$-325.77M
KGV:
-9.9182
EPS:
-1.7725
Netto-Cashflow:
$-332.79M
1W Leistung:
+2.81%
1M Leistung:
-22.11%
6M Leistung:
-52.40%
1J Leistung:
-51.69%
1-Tages-Spanne:
$17.56
$18.44
1-Wochen-Bereich:
$16.82
$18.67
52-Wochen-Spanne:
$16.24
$44.90
Legend Biotech Corp Adr Stock (LEGN) Company Profile
Firmenname
Legend Biotech Corp Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare LEGN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LEGN
Legend Biotech Corp Adr
|
17.58 | 3.34B | 797.73M | -325.77M | -332.79M | -1.7725 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Legend Biotech Corp Adr Stock (LEGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-22 | Herabstufung | TD Cowen | Buy → Hold |
| 2026-01-07 | Eingeleitet | Oppenheimer | Outperform |
| 2025-10-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-08 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-06-17 | Eingeleitet | Truist | Buy |
| 2024-05-24 | Bestätigt | H.C. Wainwright | Buy |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Buy |
| 2024-04-17 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-04-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-13 | Eingeleitet | Raymond James | Outperform |
| 2023-12-19 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-11-06 | Eingeleitet | Goldman | Buy |
| 2023-05-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-05-22 | Eingeleitet | Daiwa Securities | Buy |
| 2023-03-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-03-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-12-06 | Eingeleitet | UBS | Buy |
| 2022-11-02 | Eingeleitet | Evercore ISI | Outperform |
| 2022-11-01 | Eingeleitet | Cowen | Outperform |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-03-15 | Eingeleitet | Barclays | Overweight |
| 2022-01-31 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-21 | Eingeleitet | Piper Sandler | Overweight |
| 2021-05-18 | Eingeleitet | BTIG Research | Buy |
| 2020-07-01 | Eingeleitet | JP Morgan | Overweight |
| 2020-07-01 | Eingeleitet | Jefferies | Buy |
| 2020-06-30 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Legend Biotech Corp Adr Aktie (LEGN) Neueste Nachrichten
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Legend Biotech (NASDAQ:LEGN) Downgraded by Rothschild & Co Redburn to “Neutral” - Defense World
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns By Investing.com - Investing.com India
Legend Biotech stock rating downgraded by Rothschild Redburn on competition concerns - Investing.com
Legend Biotech (NASDAQ:LEGN) Makes Strides in Nasdaq Composite Biotech Field - Kalkine Media
Investment Analysts’ Weekly Ratings Updates for Legend Biotech (LEGN) - Defense World
Legend Biotech (LEGN) Shakes Up Board - Finviz
Legend Biotech (NASDAQ:LEGN) Sets New 12-Month LowTime to Sell? - MarketBeat
H.C. Wainwright Highlight Curative Potential of Legend Biotech Corporation (LEGN)'s Carvykti Despite Sales Miss - Finviz
82,516 Shares in Legend Biotech Corporation Sponsored ADR $LEGN Bought by Mutual of America Capital Management LLC - MarketBeat
Legend Biotech stock hits 52-week low at $18.07 By Investing.com - Investing.com South Africa
Legend Biotech stock hits 52-week low at $18.07 - Investing.com
Legend Biotech (NASDAQ:LEGN) Hits New 12-Month LowTime to Sell? - MarketBeat
Legend Biotech (LEGN) Advances Cell Therapy Innovation and Expands Oncology Pipeline - Finviz
Legend Biotech FY2025 EPS Estimate Lifted by HC Wainwright - MarketBeat
Legend Biotech (NASDAQ:LEGN) Price Target Lowered to $50.00 at HC Wainwright - Defense World
Legend Biotech (NASDAQ:LEGN) Shares Gap Down on Analyst Downgrade - Defense World
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss By Investing.com - Investing.com South Africa
H.C. Wainwright lowers Legend Biotech stock price target on Q4 sales miss - Investing.com India
Rakuten Investment Management Inc. Takes $7.58 Million Position in Legend Biotech Corporation Sponsored ADR $LEGN - MarketBeat
Legend Biotech stock rating downgraded by TD Cowen on Carvykti concerns - Investing.com South Africa
Legend Biotech stock hits 52-week low at $20.15 By Investing.com - Investing.com India
Legend Biotech (NASDAQ:LEGN) Hits New 52-Week LowHere's Why - MarketBeat
Legend Biotech stock hits 52-week low at $20.15 - Investing.com
Legend Biotech (NASDAQ:LEGN) Given “Outperform” Rating at Royal Bank Of Canada - Defense World
Raymond James reiterates Outperform rating on Legend Biotech stock By Investing.com - Investing.com India
Raymond James reiterates Outperform rating on Legend Biotech stock - Investing.com
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints By Investing.com - Investing.com South Africa
Legend Biotech stock rises as FDA draft guidance supports accelerated approval endpoints - Investing.com
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Diana Shipping inc. (NYSE:DSX) Short Interest Update - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Short Interest Up 23.3% in December - MarketBeat
Deutsche Bank reiterates Buy rating on Legend Biotech stock with $60 target - Investing.com
LEGN: CARVYKTI's rapid growth, clinical leadership, and pipeline innovation drive 2026 profitability goals - TradingView — Track All Markets
Legend Biotech Highlights Recent Business Updates at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cantor Fitzgerald and RBC Capital Stay Bullish on Legend Biotech (LEGN) - Finviz
Legend Biotech (NASDAQ:LEGN) Coverage Initiated by Analysts at Oppenheimer - Defense World
Legend Biotech (NASDAQ:LEGN) Trading Up 7.3%What's Next? - MarketBeat
Remix Therapeutics names Mythili Koneru as chief medical officer - Investing.com
Legend Biotech (NASDAQ:LEGN) Reaches New 12-Month LowWhat's Next? - MarketBeat
Legend Biotech stock hits 52-week low at 21.16 USD - Investing.com
Legend Biotech Corporation Sponsored ADR $LEGN Shares Sold by Matthews International Capital Management LLC - MarketBeat
Connective Portfolio Management LLC Acquires New Holdings in Legend Biotech Corporation Sponsored ADR $LEGN - Defense World
Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Legend Biotech (LEGN) – Investment Analysts’ Recent Ratings Changes - Defense World
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - The Motley Fool
Here is Why Legend Biotech (LEGN) Offers Such Promising Upside - Finviz
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline By Investing.com - Investing.com South Africa
Legend Biotech stock remains Overweight at Cantor Fitzgerald despite YTD decline - Investing.com India
Legend Biotech (NASDAQ:LEGN) Reaches New 52-Week LowWhat's Next? - MarketBeat
Finanzdaten der Legend Biotech Corp Adr-Aktie (LEGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):